Howard Weintraub

Howard Weintraub

Auto-generated profile, based on publicly available information

Howard Weintraub

New York University School of Medicine, New York, NY

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in JACC
Verified
Journal Article
Closed access
JNJonathan Newman
Jonathan Newman
ASArthur Z. Schwartzbard
Arthur Z. Schwartzbard
HWHoward S. Weintraub
Howard S. Weintraub
IGIra J. Goldberg
Ira J. Goldberg
JBJeffrey S. Berger
Jeffrey S. Berger

1 June 2017 in The American Journal of Medicine
Verified
Journal Article
Closed access
SBSripal Bangalore
Sripal Bangalore
BTBora Toklu
Bora Toklu
EGEugenia Gianos
Eugenia Gianos
ASArthur Schwartzbard
Arthur Schwartzbard
HWHoward Weintraub
Howard Weintraub
FMFranz H. Messerli
Franz H. Messerli

1 June 2008 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MDMichael H. Davidson
Michael H. Davidson
MCMarshall A. Corson
Marshall A. Corson
MAMark J. Alberts
Mark J. Alberts
JAJeffrey L. Anderson
Jeffrey L. Anderson
PGPhilip B. Gorelick
Philip B. Gorelick
HWHoward S. Weintraub
Howard S. Weintraub

12 August 2014 in Circulation
Verified
Journal Article
Open access
PDF file
BDBethany Doran
Bethany Doran
YGYu Guo
Yu Guo
JXJinfeng Xu
Jinfeng Xu
HWHoward Weintraub
Howard Weintraub
SMSamia Mora
Samia Mora
SBSripal Bangalore
Sripal Bangalore
Background—: National and international guidelines recommend fasting lipid panel measurement for risk stratification of patients for prevention of cardiovascular events. However, the prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol (LDL-C) is uncertain. Methods and Results—: Patients enrolled in the National Health and Nutrition Examination Survey III (NHANES-III), a nationally representative cross-sectional survey performed from 1988 to 1994, were stratified on the basis of fasting status (≥8 or <8 hours) and followed for a mean of 14.0 (±0.22) years. Propensity score matching was used to assemble fasting and nonfasting cohorts with similar baseline characteristics. The risk of outcomes as a function of LDL-C and fasting status was assessed with the use of receiver operating characteristic curves and bootstrapping methods. The interaction between fasting status and LDL-C was assessed with Cox proportional hazards modeling. Primary outcome was all-cause mortality. Secondary outcome was cardiovascular mortality. One-to-one matching based on propensity score yielded 4299 pairs of fasting and nonfasting individuals. For the primary outcome, fasting LDL-C yielded prognostic value similar to that for nonfasting LDL-C (C statistic=0.59 [95% confidence interval, 0.57–0.61] versus 0.58 [95% confidence interval, 0.56–0.60]; P =0.73), and LDL-C by fasting status interaction term in the Cox proportional hazards model was not significant ( P interaction =0.11). Similar results were seen for the secondary outcome (fasting versus nonfasting C statistic=0.62 [95% confidence interval, 0.60–0.66] versus 0.62 [95% confidence interval, 0.60–0.66]; P =0.96; P interaction =0.34). Conclusions—: Nonfasting LDL-C has prognostic value similar to that of fasting LDL-C. National and international agencies should consider reevaluating the recommendation that patients fast before obtaining a lipid panel.

1 September 2010 in Cardiology in Review
Verified
Journal Article
Closed access
DWDaniel Weitz
Daniel Weitz
HWHoward Weintraub
Howard Weintraub
EFEdward Fisher
Edward Fisher
ASArthur Z. Schwartzbard
Arthur Z. Schwartzbard
Omega-3 fatty acids, which are found abundantly in fish oil, are increasingly being used in the management of cardiovascular disease. It is clear that fish oil, in clinically used doses (typically 4 g/d of eicosapentaenoic acid and docosahexaenoic acid) reduce high triglycerides. However, the role of omega-3 fatty acids in reducing mortality, sudden death, arrhythmias, myocardial infarction, and heart failure has not yet been established. This review will focus on the current clinical uses of fish oil and provide an update on their effects on triglycerides, coronary artery disease, heart failure, and arrhythmia. We will explore the dietary sources of fish oil as compared with drug therapy, and discuss the use of fish oil products in combination with other commonly used lipid-lowering agents. We will examine the underlying mechanism of fish oil's action on triglyceride reduction, plaque stability, and effect in diabetes, and review the newly discovered anti-inflammatory effects of fish oil. Finally, we will examine the limitations of current data and suggest recommendations for fish oil use.

1 January 2016 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
SBSripal Bangalore
Sripal Bangalore
RFRobert Fakheri
Robert Fakheri
BTBora Toklu
Bora Toklu
GOGbenga Ogedegbe
Gbenga Ogedegbe
HWHoward Weintraub
Howard Weintraub
FMFranz H. Messerli
Franz H. Messerli